News for DURECT Corporation (DRRX)

Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PR NewswireCUPERTINO, Calif., Nov. 25, 2024 CUPERTINO, Calif., Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceuti

DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsJim Brown - Co-Founder, Chief Executive...

Durect (DRRX) delivered earnings and revenue surprises of 17.65% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) experienced a notable stock surge with shares rising by 5.01%. The stock was last reported at $4.40 per share with a trading vol

Aug 13, 2024 / 08:30PM GMTOperator Ladies and gentlemen, welcome to the DURECT Corporation second-quarter 2024 earnings conference call. (Operator Instructions)

DURECT Corporation (NASDAQ:NASDAQ:DRRX) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ETCompany ParticipantsTim Papp - CFO & SecretaryJim...

Durect (DRRX) delivered earnings and revenue surprises of 29.41% and 12.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Potential insights on DURECT Corporation's upcoming Q2 earnings results: EPS Estimate of -$0.17 (+63.0% Y/Y) and Revenue Estimate of $2.49M (+19.7% Y/Y).

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday.

On Wednesday, 311 stocks hit new 52-week lows.

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new ...

DURECT Corporation (NASDAQ:DRRX) Q4 2020 Earnings Conference Call March 04, 2021, 04:30 PM ET Company Participants Mike Arenberg - CFO Jim Brown - President & CEO WeiQi Lin - EVP,...

Companies Reporting Before The Bell • Toro (NYSE:TTC) is expected to report quarterly earnings at $0.75 per share on revenue of $851.38 ...

Covina CA, March 02, 2021 (GLOBE NEWSWIRE) -- Global Oral Solid Dosage Excipients Market accounted for US$ 2.8 billion in 2020 and is estimated to be US$ ...

CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3) 9 ...

Today's Daily Dose brings you news about encouraging results of Cassava's Alzheimer's trial; FDA approval of DURECT's post-operative pain relief depot product, Posimir, Immunovant pausing IMVT-1401 trials and Travere's pivotal study of Sparsentan in focal segmental glomerulosclerosis yielding positive results.